CONVINCE in the context of existing evidence on haemodiafiltration

Robin W M Vernooij; Michiel L Bots; Giovanni F M Strippoli; Bernard Canaud; Krister Cromm; Mark Woodward; Peter J Blankestijn; CONVINCE scientific committee

doi:10.1093/ndt/gfac019

CONVINCE in the context of existing evidence on haemodiafiltration

Nephrol Dial Transplant. 2022 May 25;37(6):1006-1013. doi: 10.1093/ndt/gfac019.

Authors

Robin W M Vernooij^{1

2}, Michiel L Bots², Giovanni F M Strippoli^{3

4}, Bernard Canaud⁵, Krister Cromm⁶, Mark Woodward^{7

8

9}, Peter J Blankestijn¹; CONVINCE scientific committee

Collaborators

CONVINCE scientific committee:
Andrew Davenport, Bernard Canaud, Claudia Barth, Giovanni Strippoli, Jörgen Hegbrant, Kathrin Fischer, Krister Cromm, Mariëtta Török, Mark Woodward, Matthias Rose, Michiel Bots

Affiliations

¹ Department of Nephrology and Hypertension, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands.
² Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands.
³ Department of Emergency and Organ Transplantation, University of Bari, Bari BA, Italy.
⁴ School of Public Health, University of Sydney, Sydney, Australia.
⁵ Montpellier University, School of Medicine, Montpellier, France & Global Medical Office, FMC Deutschland, Bad Homburg, Germany.
⁶ Fresenius Medical Care Deutschland GmbH, Global Medical Office, Bad Homburg, Germany.
⁷ The George Institute for Global Health, University of Oxford, Oxford, UK.
⁸ The George Institute for Global Health, University of New South Wales, Sydney, New South Wales, Australia.
⁹ Department of Epidemiology, Johns Hopkins University, Baltimore, MD, USA.

Abstract

Haemodiafiltration (HDF) provides a greater removal of larger solutes and protein-bound compounds than conventional high-flux haemodialysis (HD). There are indications that the patients receiving the highest convection volumes of HDF result in improved survival compared with HD. However, the comparative efficacy of HDF versus HD remains unproven. Here we provide a comparative account of the methodology and aims of 'the comparison of high-dose HDF with high-flux HD' (CONVINCE) study in the context of the totality of evidence and how this study will contribute to reaching a higher level of certainty regarding the comparative efficacy of HDF versus HD in people with end-stage kidney disease.

Publication types

Editorial
Research Support, Non-U.S. Gov't

MeSH terms

Convection
Hemodiafiltration* / methods
Humans
Kidney Failure, Chronic* / therapy
Renal Dialysis / methods

Associated data

NTR/NTR 7138